Premium
Comparison of intermittent or continuous methotrexate plus 6‐mercaptopurine in regimens for standard‐risk acute lymphoblastic leukemia in childhood (JCCLSG‐S811)
Author(s) -
Koizumi Shoichi,
Fujimoto Takeo,
Takeda Takeo,
Yatabe Micho,
Utsumi Jirou,
Mimaya Junichi,
Ninomiya Tsuneo,
Yanai Masanori
Publication year - 1988
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19880401)61:7<1292::aid-cncr2820610703>3.0.co;2-o
Subject(s) - medicine , mercaptopurine , methotrexate , lymphoblastic leukemia , oncology , acute lymphocytic leukemia , leukemia , intensive care medicine
From 1981 to 1983, 131 previously untreated patients with acute lymphoblastic leukemia (ALL) standard‐risk group were entered to the protocol JCCLSG‐S811. Of 119 eligible patients, 115 (96.6%) attained complete remission by treatment with prednisone (PRD) plus vincristine (VCR) or vindesine (VDS). After preventive central nervous system (CNS) therapy including 18 Gy cranial irradiation and three doses of intrathecal methotrexate (MTX), the patients were assigned randomly to the two maintenance chemotherapies, Regimen A and Regimen B. Regimen A (intermittent regimen) consisted of PRD (120 mg/m 2 /day by mouth for 5 days) plus 6‐mercaptopurine (6MP) (175 mg/m 2 /day by mouth for 5 days) plus VCR (2.0 mg/m 2 intravenously) alternating biweekly with MTX (225 mg/m 2 intravenously). Regimen B (continuous regimen) consisted of 6MP (50 mg/m 2 /day by mouth) plus MTX (20 mg/m 2 / week by mouth) combined with pulses of PRD and VCR (the same dosages as Regimen A) every 4 weeks. As the late intensification therapy (LIT), five courses of high‐dose MTX (2000 mg/m 2 per dose per week intravenously for three doses every 12 weeks) with leucovorin rescue were administered to all patients who were in continuous complete remission (CCR) for more than 2 years. Sixty and 55 patients, respectively, were registered in Regimen A and B. The CCR rates in Regimen A and B were 75.1% ± 5.8% (mean ± 1 SE) and 49.7% ± 7.3% ( P < 0.01) at 4 years, and 72.1% ± 6.3% and 49.7% ± 7.3% ( P < 0.05) at 5 years, respectively. In Regimen B, CNS and testicular relapses increased after 3 years of CCR. In addition, the patients in Regimen B had a much higher incidence of infections than Regimen A. The LIT did not seem to have important effects on the duration of CCR. From these data we conclude that the intermittent cyclic regimen of 6MP and MTX may be more effective as compared to the continuous administration of these drugs in the maintenance chemotherapy.